Citations

Showing 10 of 108119 citations.

In adults aged 75 to 76 y, systematic AF screening reduced morbidity and mortality at 6 y
Yousufuddin, Mohammed , Jahangir, Arshad

Mayo Clinic

Annals of Internal Medicine | January 3, 2022 | Volume: 175 | Issue: 1 | Pages: JC9

10.7326/j21-0012 | PMID 34978858 Get It

In older patients at high risk for stroke, intensive AF screening with an implantable loop recorder did not reduce stroke
Yousufuddin, Mohammed, Jahangir, Arshad, Yousufuddin, Mohammed, Jahangir, Arshad

Mayo Clinic

Annals of Internal Medicine | January 3, 2022 | Volume: 175 | Issue: 1 | Pages: JC8

10.7326/j21-0011 | PMID 34978859 Get It

A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy
Brien, Marie‐Eve , Gaudreault, Virginie, Hughes, Katia, Heazell, Alexander , Heazell, Alexander E P , Hayes, Dexter J. L. , Girard, Sylvie

Mayo Clinic

Journal of Clinical Medicine | January 3, 2022 | Volume: 11 | Issue: 1 | Pages: 225

10.3390/jcm11010225 | PMID 35011965 Get It

Blockade of the interleukin-1 (IL-1) pathway has been used therapeutically in several inflammatory diseases including arthritis and cryopyrin-associated periodic syndrome (CAPS). These conditions frequently affect women of childbearing age and continued usage of IL-1 specific treatments throughout pregnancy has been reported. IL-1 is involved in pregnancy complications and its blockade could have therapeutic potential. We systematically reviewed all reported cases of IL-1 blockade in human pregnancy to assess safety and perinatal outcomes. We searched several databases to find reports of specific blockade of the IL-1 pathway at any stage of pregnancy, excluding broad spectrum or non-specific anti-inflammatory intervention. Our literature search generated 2439 references of which 22 studies included, following extensive review. From these, 88 different pregnancies were assessed. Most (64.8%) resulted in healthy term deliveries without any obstetrical/neonatal complications. Including pregnancy exposed to Anakinra or Canakinumab, 12 (15.0%) resulted in preterm birth and one stillbirth occurred. Regarding neonatal complications, 2 cases of renal agenesis (2.5%) were observed, and 6 infants were diagnosed with CAPS (7.5%). In conclusion, this systematic review describes that IL-1 blockade during pregnancy is not associated with increased adverse perinatal outcomes, considering that treated women all presented an inflammatory disease associated with elevated risk of pregnancy complications.
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome
Kaddoura, Marcella , Binder, Moritz , Dingli, David , Lacy, Martha Q. , Gertz, Morie A. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Gertz, Morie A , Dispenzieri, Angela , Hwa, Yi L , Leung, Nelson , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Tschautscher, Marcella , Binder, Moritz , Dingli, David , Lin, Yi , Buadi, Francis K. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | January 3, 2022 | Volume: 97 | Issue: 3 | Pages: 267-273

10.1002/ajh.26439 | PMID 34978743 Get It

AbstractAchievement of a complete response (CR) in multiple myeloma (MM) correlates with improvement in survival outcomes; however, its impact on prognostic variables at baseline outside of clinical trial settings is not well described. We sought to determine the impact of achieving a CR within 2 years from diagnosis, its effect on the prognostic value of fluorescence in situ hybridization (FISH) and International Staging System (ISS) risk, and examined additional predictors of outcome among those achieving a CR in a routine clinical setting. We evaluated 1869 newly diagnosed MM patients who had ≥ 2 monoclonal protein immunofixation studies in the serum and urine available within 24 months from diagnosis, categorizing those with ≥ 2 negative serum and urine immunofixations as achieving CR. With a landmark at 24 months, median progression‐free survival (PFS) for CR versus non‐CR patients was 29.8 versus 20.9 months (p ≤ .0002); median overall survival (OS) was 104 versus 70 months (p < .0001). The impact of achieving a CR was retained after adjusting for FISH, ISS, sex, transplant status, and involved heavy chain. Baseline FISH and ISS stage were not associated with PFS or OS among patients achieving a CR. The following variables were found as predictors of inferior OS within the CR cohort: age > 75 years, male gender, hypoalbuminemia, and non‐immunoglobulin G involved heavy chain. Our study confirms that achievement of CR within 2 years from diagnosis is associated with improvement in survival outcomes and neutralization of the impact of FISH and ISS risk, thereby confirming observations from the clinical trial setting among a clinical practice cohort.
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease
Abeykoon, Jithma P. , Dasari, Surendra , Ranatunga, Wasantha , Tischer, Alexander , Ravindran, Aishwarya , Tobin, W. Oliver , Nowakowski, Kevin E., Ruan, Gordon , Bennani, Nabila Nora, Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Patnaik, Mrinal M. , Wu, Xiaosheng , Lasho, Terra L. , Ranatunga, Wasantha K, Manske, Michelle K. , Ravindran, Aishwarya , Tobin, William Oliver, Ruan, Gordon J , Shah, Mithun V , Ryu, Jay H , Patnaik, Mrinal , Wu, Xiaosheng , Witzig, T.E. , Goyal, Guarav , Tobin, W Oliver , Vassallo, Robert , Tischer, Alexander , Rech, Karen L. , Young, Jason R. , Flanagan, Eoin P. , Shah, Meera , Koster, Matthew J. , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

American Journal of Hematology | January 3, 2022 | Volume: 97 | Issue: 3 | Pages: 293-302

10.1002/ajh.26441 | PMID 34978715 Get It

AbstractErdheim–Chester disease (ECD) is a histiocytic neoplasm that predominantly harbors mitogen‐activated protein kinase (MAPK) pathway variants. MAPK inhibitors typically are effective treatments, but mutations outside the MAPK pathway, such as CSF1R variants, may cause refractory ECD. We describe a patient with a novel somatic mutation in CSF1R (CSF1RR549_E554delinsQ) that resulted in refractory ECD affecting the central nervous system. Cell model studies, RNA sequencing analysis, and in silico protein modeling suggested that she had a gain‐of‐function mutation occurring in a region critical for autoinhibition. The patient was treated with pexidartinib, a CSF1R inhibitor, and has had a complete clinical and metabolic response lasting more than 1.5 years to date. To our knowledge, this is the first report to describe successful treatment of a patient with ECD by using an agent that specifically targets CSF1R. This case also highlights the critical role of individualized molecular profiling to identify novel therapeutic targets in ECD.
Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors
Prete, Alessandro , Subramanian, Anuradhaa , Tsagarakis, Stylianos , Lang, Katharina, Macech, Magdalena, Delivanis, Danae A., Pupovac, Ivana D. , Reimondo, Giuseppe , Marina, Ljiljana V. , Deutschbein, Timo , Balomenaki, Maria, Jenkinson, Carl , Bednarczuk, Tomasz , Zhang, Catherine D , Dušek, Tina , Diamantopoulos, Aristidis, Asia, Miriam, Kondracka, Agnieszka , Li, Dingfeng, Masjkur, Jimmy R., Ueland, Grethe Å., Dennedy, Michael Conall , Beuschlein, Felix , Tabarin, Antoine, Ivović, Miomira , Kastelan, Darko, Ambroziak, Urszula , Vassiliadi, Dimitra A. , Taylor, Angela E. , Sitch, Alice , Nirantharakumar, Krishnarajah , Arlt, Wiebke , Investigators*, ENSAT EURINE-ACT, Biehl, Michael , Sutcliffe, Robert P. , Kaštelan, Darko , Fragoso, Maria Candida Barisson Villares , Papathomas, Thomas , Bancos, Irina , Chortis, Vasileios , Tsagarakis, Stylianos , Pupovac, Ivana D , Reimondo, Giuseppe , Marina, Ljiljana V , Deutschbein, Timo , O'Reilly, Michael W , Gilligan, Lorna C , Jenkinson, Carl , Bednarczuk, Tomasz , Zhang, Catherine D , Dusek, Tina , Kondracka, Agnieszka , Quinkler, Marcus , Dennedy, M Conall , Beuschlein, Felix , Fassnacht, Martin , Ivović, Miomira , Terzolo, Massimo , Young, W F , Manolopoulos, Konstantinos N , Ambroziak, Urszula , Vassiliadi, Dimitra A , Taylor, Angela E , Sitch, Alice J , Nirantharakumar, Krishnarajah , Arlt, Wiebke , Prete, Alessandro , Kastelan, Darko , Subramanian, Anuradhaa , Lang, Katharina, Macech, Magdalena, Delivanis, Danae A., Diamantopoulos, Aristidis, Asia, Miriam, Li, Dingfeng, Masjkur, Jimmy R., Ueland, Grethe Å., Tabarin, Antoine, Investigators*, ENSAT EURINE-ACT

Mayo Clinic

Annals of Internal Medicine | January 3, 2022 | Volume: 175 | Issue: 3 | Pages: 325-334

10.7326/m21-1737 | PMID 34978855 Get It

Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Xu-Monette, Zijun Y., Wei, Li, Fang, Xiaosheng , Au, Qingyan, Nunns, Harry, Nagy, Máté, Tzankov, Alexandar , Zhu, Feng, Visco, Carlo , Bhagat, Govind , Dybkær, Karen , Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Sun, Xiaoping , Han, Xin, Go, Heounjeong, Ferreri, Andrés J.M., Møller, Michael , Parsons, Benjamin M. , Piris, Miguel A., Li, Yong, Xu, Bing, Albitar, Maher, You, Hua, Young, Ken H., Xu‐Monette, Zijun Y. , Zu, Youli , Young, Ken H. , Ponzoni, Maurilio , Møller, Michael Boe , Parsons, Benjamin M , van Krieken, J Han , Winter, Jane N , Tzankov, Alexandar , Dybkaer, Karen , Young, Ken H , Bhagat, Govind , Zu, Youli , Xu-Monette, Zijun Y , Wei, Li, Fang, Xiaosheng , Au, Qingyan, Nunns, Harry, Nagy, Máté, Zhu, Feng, Visco, Carlo , Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Sun, Xiaoping , Han, Xin, Go, Heounjeong, Ferreri, Andrés J.M., Piris, Miguel A., Li, Yong, Xu, Bing, Albitar, Maher, You, Hua, Young, Ken H.

Mayo Clinic

Clinical Cancer Research | January 3, 2022 | Volume: 28 | Issue: 5 | Pages: 972-983

10.1158/1078-0432.ccr-21-2949 | PMID 34980601 Get It

Abstract Purpose: Diffuse large B-cell lymphoma (DLBCL) is molecularly and clinically heterogeneous, and can be subtyped according to genetic alterations, cell-of-origin, or microenvironmental signatures using high-throughput genomic data at the DNA or RNA level. Although high-throughput proteomic profiling has not been available for DLBCL subtyping, MYC/BCL2 protein double expression (DE) is an established prognostic biomarker in DLBCL. The purpose of this study is to reveal the relative prognostic roles of DLBCL genetic, phenotypic, and microenvironmental biomarkers. Experimental Design: We performed targeted next-generation sequencing; IHC for MYC, BCL2, and FN1; and fluorescent multiplex IHC for microenvironmental markers in a large cohort of DLBCL. We performed correlative and prognostic analyses within and across DLBCL genetic subtypes and MYC/BCL2 double expressors. Results: We found that MYC/BCL2 double-high-expression (DhE) had significant adverse prognostic impact within the EZB genetic subtype and LymphGen-unclassified DLBCL cases but not within MCD and ST2 genetic subtypes. Conversely, KMT2D mutations significantly stratified DhE but not non-DhE DLBCL. T-cell infiltration showed favorable prognostic effects within BN2, MCD, and DhE but unfavorable effects within ST2 and LymphGen-unclassified cases. FN1 and PD-1–high expression had significant adverse prognostic effects within multiple DLBCL genetic/phenotypic subgroups. The prognostic effects of DhE and immune biomarkers within DLBCL genetic subtypes were independent although DhE and high Ki-67 were significantly associated with lower T-cell infiltration in LymphGen-unclassified cases. Conclusions: Together, these results demonstrated independent and additive prognostic effects of phenotypic MYC/BCL2 and microenvironment biomarkers and genetic subtyping in DLBCL prognostication, important for improving DLBCL classification and identifying prognostic determinants and therapeutic targets.
Horseshoe Adrenal Gland
Bajaj, Suryansh , Jain, Manoj , Bhatt, Shweta

Mayo Clinic

No container title available | January 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20225808 Get It

Meta-analysis Integrated With Multi-omics Data Analysis to Elucidate Pathogenic Mechanisms of Age-Related Knee Osteoarthritis in Mice
Iijima, Hirotaka , Gilmer, Gabrielle, Wang, Kai, Sivakumar, Sruthi, Evans, Christopher, Matsui, Yusuke , Ambrosio, Fabrisia , Iijima, Hirotaka , Gilmer, Gabrielle, Wang, Kai, Sivakumar, Sruthi, Evans, Christopher, Matsui, Yusuke , Ambrosio, Fabrisia

Mayo Clinic

The Journals of Gerontology: Series A | January 3, 2022 | Volume: 77 | Issue: 7 | Pages: 1321-1334

10.1093/gerona/glab386 | PMID 34979545 Get It

Abstract Increased mechanistic insight into the pathogenesis of knee osteoarthritis (KOA) is needed to develop efficacious disease-modifying treatments. Though age-related pathogenic mechanisms are most relevant to the majority of clinically presenting KOA, the bulk of our mechanistic understanding of KOA has been derived using surgically induced posttraumatic OA (PTOA) models. Here, we took an integrated approach of meta-analysis and multi-omics data analysis to elucidate pathogenic mechanisms of age-related KOA in mice. Protein-level data were integrated with transcriptomic profiling to reveal inflammation, autophagy, and cellular senescence as primary hallmarks of age-related KOA. Importantly, the molecular profiles of cartilage aging were unique from those observed following PTOA, with less than 3% overlap between the 2 models. At the nexus of the 3 aging hallmarks, advanced glycation end product (AGE)/receptor for AGE (RAGE) emerged as the most statistically robust pathway associated with age-related KOA. This pathway was further supported by analysis of mass spectrometry data. Notably, the change in AGE–RAGE signaling over time was exclusively observed in male mice, suggesting sexual dimorphism in the pathogenesis of age-induced KOA in murine models. Collectively, these findings implicate dysregulation of AGE–RAGE signaling as a sex-dependent driver of age-related KOA.
A Preclinical Study of Standard Versus Accelerated Transcranial Magnetic Stimulation for Depression in Adolescents
Seewoo, Bhedita J. , Hennessy, Lauren A. , Jaeschke, Liz A., Mackie, Leah A., Etherington, Sarah J. , Dunlop, Sarah A. , Croarkin, Paul E. , Rodger, Jennifer , Croarkin, Paul E , Jaeschke-Angi, Liz

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | January 3, 2022 | Volume: 32 | Issue: 3 | Pages: 187-193

10.1089/cap.2021.0100 | PMID 34978846 Get It